• 1
    Byrd JC, Mrozek K, Dodge R, et al. Pre-treatment cytogenetics predict initial induction success and overall survival in adult patients with de novo acute myeloid leukemia: results from CALGB 8461 [abstract 1912]. Blood. 2001; 98: 457A.
  • 2
    Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica. 2004; 89: 10821090.
  • 3
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998; 92: 23222333.
  • 4
    Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica. 2004; 89: 528540.
  • 5
    Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004; 18: 120125.
  • 6
    Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood. 2000; 95: 7277.
  • 7
    Kern W, Voskova D, Schnittger S, et al. Early assessment of minimal residual disease by multiparameter flow cytometry identifies patients at high risk of relapse after allogeneic stem cell transplantation following reduced intensity conditioning for advanced acute myeloid leukemia. Blood. 2003; 102: 481A482A.
  • 8
    Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21: 46424649.
  • 9
    Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003; 21: 256265.
  • 10
    Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003; 101: 6470.
  • 11
    Buchner T, Berdel W, Wormann B, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol. 2002; 6: 4659.
  • 12
    Raanani P. Minimal residual disease in hematological malignancies. Acta Haematol. 2004; 112: 57.
  • 13
    Raanani P, Ben Bassat I. Detection of minimal residual disease in acute myelogenous leukemia. Acta Haematol. 2004; 112: 4054.
  • 14
    Loffler H, Raststetter J. Atlas of clinical hematology, 6th revised edition. New York: Springer, 2005.
  • 15
    JaffeE, Lee HarrisN, SteinH, VardimanJW, editors. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
  • 16
    Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002; 16: 5359.
  • 17
    MitelmanF, editor. An international system for human cytogenetic nomenclature. Basel, Switzerland: Karger, 1995.
  • 18
    Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA(+), AML1-ETO+, or CBFB-MYH11(+) acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003; 102: 27462755.
  • 19
    Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol. 2004; 112: 6878.
  • 20
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 21
    Schnittger S, Kohlmann A, Haferlach T, et al. Acute myeloid leukemia (AML) with partial tandem duplication of the MLL-gene (MLL-PTD) can be discriminated from MLL-translocations based on specific gene expression profiles. Blood, 2002; 100: 310A311A.
  • 22
    Marcucci G, Mrozek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461. J Clin Oncol. 2004; 22: 24102418.
  • 23
    Freireich EJ, Cork A, Stass SA, et al. Cytogenetics for detection of minimal residual disease in acute myeloblastic-leukemia. Leukemia. 1992; 6: 500506.
  • 24
    Konopleva M, Cheng SC, Cortes JE, et al. Independent prognostic significance of Day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica. 2003; 88: 733736.
  • 25
    Buonamici SS, Ottaviani EE, Testoni NN, Visani GG, Saglio GG, Martinelli GG. Real-time quantitation of minimal residual disease in inv(16) positive acute myeloid leukemia can predict clinical relapse and identify patients in a curable state [abstract]. Blood. 2000; 96: 312A.
  • 26
    San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001; 98: 17461751.
  • 27
    El Rifai W, Ruutu T, Elonen E, Volin L, Knuutila S. Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission. Blood. 1997; 89: 33303334.
  • 28
    Nylund SJ, Ruutu T, Saarinen U, Larramendy ML, Knuutila S. Detection of minimal residual disease using fluorescence DNA in-situ hybridization—a follow-up-study in leukemia and lymphoma patients. Leukemia. 1994; 8: 587594.
  • 29
    Bernell P, Jakobsson B, Arvidsson I, Hast R. Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapses in acute leukemia. Br J Haematol. 1996; 95: 662672.
  • 30
    Amare P, Baisane C, Saikia T, Nair R, Gawade H, Advani S. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias. Cancer Genet Cytogenet. 2004; 131: 125134.
  • 31
    Mancini M, Cedrone M, Diverio D, et al. Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients. Leukemia. 2000; 14: 364368.